chevron_leftBack
As of 24 April 2025, Alivus Life Sciences Ltd. has a market cap of $1.47B USD, ranking #6502 globally and #447 in India. It ranks #611 in the Healthcare sector, and #131 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$1.47BUSD
125.47B INR
Enterprise Value
$1.42BUSD
121.16B INR
Revenue (TTM)
$266.49MUSD
22.74B INR
EBITDA (TTM)
$72.64MUSD
6.21B INR
Net Income (TTM)
$51.76MUSD
4.42B INR
EBITDA Margin
27%
Profit Margin
19%
PE Ratio
28.5
Company Profile
Country (HQ)
Sector
Healthcare
CEO
Yasir Rawjee
open_in_new
Employees
2,014
Founded
2011
Website
alivus.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 3.2% | 5.7% | -7.3% | -11% | 1.8% | 24% |
Upcoming Earnings
Earnings Date
Thu, Apr 24
Today
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ALIVUS
Alivus Life Sciences Ltd
ISIN: INE03Q201024
Shares Out.:
Shares Outstanding:
122.537M1
Shares Float:
30.638M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
1.02K INR | |
|
543322
(ALIVUS)
Alivus Life Sciences Ltd
ISIN: INE03Q201024
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
987.55 INR |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Alivus Life Sciences Ltd.
Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company’s APIs are used in various therapeutic segments, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, and anti-infectives. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was incorporated in 2011 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.
